JPH08500365A - 皮膚浸透力を高めた医薬組成物 - Google Patents
皮膚浸透力を高めた医薬組成物Info
- Publication number
- JPH08500365A JPH08500365A JP6515882A JP51588294A JPH08500365A JP H08500365 A JPH08500365 A JP H08500365A JP 6515882 A JP6515882 A JP 6515882A JP 51588294 A JP51588294 A JP 51588294A JP H08500365 A JPH08500365 A JP H08500365A
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- piroxicam
- polyethylene glycol
- solution
- weight percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035515 penetration Effects 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- 229960002702 piroxicam Drugs 0.000 claims abstract description 42
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000011159 matrix material Substances 0.000 claims abstract description 30
- 239000013543 active substance Substances 0.000 claims abstract description 19
- 238000010521 absorption reaction Methods 0.000 claims abstract description 16
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 11
- 239000003623 enhancer Substances 0.000 claims abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 26
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 15
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 15
- 229960000890 hydrocortisone Drugs 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 9
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 claims description 9
- 239000005642 Oleic acid Substances 0.000 claims description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- 239000002998 adhesive polymer Substances 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 3
- GUSTUIJJPMXTTI-UHFFFAOYSA-N 1-dodecylazepane Chemical compound CCCCCCCCCCCCN1CCCCCC1 GUSTUIJJPMXTTI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- CYKDLUMZOVATFT-UHFFFAOYSA-N ethenyl acetate;prop-2-enoic acid Chemical group OC(=O)C=C.CC(=O)OC=C CYKDLUMZOVATFT-UHFFFAOYSA-N 0.000 claims description 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 7
- 239000000853 adhesive Substances 0.000 abstract description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 47
- 239000000203 mixture Substances 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 21
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000037317 transdermal delivery Effects 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- 206010049589 Afterbirth pain Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ピロキシカムを含む活性物質、接着性ポリマー、吸収補助剤および浸透促進 剤からなるマトリックスからなり、前記吸収補助剤がジメチルスルホキシド、ジ メチルアセトアミド、ジメチルホルムアミド、ポリエチレングリコール、プロピ レングリコール、ポリオキシエチレンエステル類、アルカールアミン類、アルキ ルアミン類、ジエチレングリコールモノエチルエーテルおよびN−アルキルピロ リドンの群から選択される1またはそれ以上であり、そして前記浸透促進剤がア ルキレングリコール誘導体、1−アルキルアザシクロヘプタン−2−オン、脂肪 酸およびそれらの誘導体、脂肪酸アルカノールアミド類およびポリエチレングリ コール誘導体から選択される1またはそれ以上であることを特徴とする経皮デリ バリーシステム。 2.前記活性物質がマトリックスの重量パーセントに基づき0.5〜25%を含 む、請求項1記載のシステム。 3.前記活性物質がピロキシカムと共に抗炎症性ステロイドを含む、請求項1ま たは2記載のシステム。 4.前記抗炎症性ステロイドがコルチゾン、ヒドロコルチゾン、プレドニゾロン 、デキサメタゾンおよびそれらの誘導体の群から選択された1またはそれ以上で ある、請求項3記載のシステム。 5.前記抗炎症性ステロイドがマトリックスの重量パーセントに基づき0.5〜 15.0%を含む、請求項3または4記載のシステム。 6.前記接着性ポリマーが酢酸ビニル−アクリレートマルチポリマーである、請 求項1記載のシステム。 7.前記接着性ポリマーがマトリックスの重量パーセントに基づき35〜90% を含む、請求項1または6記載のシステム。 8.前記吸収補助剤がマトリックスの重量パーセントに基づき9〜40%を含む 、請求項1記載のシステム。 9.前記浸透促進剤がプロピレングリコール、1−ドデシルアザシクロヘプタン −2−オン、オレイン酸、ラウリルジエタノールアミド、ポリエチレングリコー ル200モノラウレート、ポリエチレングリコール300モノラウレートおよび ポリエチレングリコール400モノラウレートの群から選択される1またはそれ 以上である、請求項1記載のシステム。 10.前記浸透促進剤がマトリックスの重量パーセントに基づき0.5〜10. 0%を含む、請求項1または9記載のシステム。 11.前記マトリックスが1または複数のラミネート層からなる、請求項1記載 のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR920027130 | 1992-12-31 | ||
KR1992/27130 | 1992-12-31 | ||
PCT/KR1993/000127 WO1994015609A1 (en) | 1992-12-31 | 1993-12-31 | Enhanced pharmaceutical compositions for skin penetration |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08500365A true JPH08500365A (ja) | 1996-01-16 |
JP2847578B2 JP2847578B2 (ja) | 1999-01-20 |
Family
ID=19348264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6515882A Expired - Fee Related JP2847578B2 (ja) | 1992-12-31 | 1993-12-31 | 皮膚浸透力を高めた医薬組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5916587A (ja) |
EP (1) | EP0676962B9 (ja) |
JP (1) | JP2847578B2 (ja) |
KR (1) | KR100212961B1 (ja) |
AT (1) | ATE202476T1 (ja) |
AU (2) | AU5718494A (ja) |
BR (1) | BR9307754A (ja) |
CA (1) | CA2153166A1 (ja) |
DE (1) | DE69330388T2 (ja) |
ES (1) | ES2160623T3 (ja) |
PT (1) | PT676962E (ja) |
RU (1) | RU2110261C1 (ja) |
WO (1) | WO1994015609A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522488A (ja) * | 1998-08-12 | 2002-07-23 | エドコ・トレイディング・アンド・レプレゼンテーション・カンパニー・リミテッド | ニメスリドを含む局所用医薬組成物 |
JP2005047908A (ja) * | 2003-07-16 | 2005-02-24 | Taisho Pharmaceut Co Ltd | 外用消炎鎮痛剤組成物 |
JP2013527197A (ja) * | 2010-05-27 | 2013-06-27 | 株式会社エービーサイズ | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
WO2014061728A1 (ja) | 2012-10-17 | 2014-04-24 | 味の素株式会社 | 化粧料組成物 |
JP5758050B2 (ja) * | 2012-06-20 | 2015-08-05 | 久光製薬株式会社 | 貼付剤 |
JP2016033161A (ja) * | 2010-06-17 | 2016-03-10 | 大正製薬株式会社 | 外用組成物 |
JP2016515572A (ja) * | 2013-04-04 | 2016-05-30 | ヒュンダイ ファーム カンパニー リミテッド | 皮膚透過が改善された外用剤組成物 |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19526864A1 (de) * | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
KR980000439A (ko) * | 1996-06-28 | 1998-03-30 | 김준웅 | 케토프로펜 경피투여 시스템 |
WO2000051575A1 (en) * | 1999-03-01 | 2000-09-08 | Amarin Technologies S.A. | Transdermal device comprising non-steroidal anti-inflammatory drugs incorporated in acrylic adhesive polymer matrix |
KR100393478B1 (ko) * | 2000-03-29 | 2003-08-06 | 주식회사종근당 | 자가유화 매트릭스형 경점막·경피흡수제제 |
US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US6803420B2 (en) | 2001-05-01 | 2004-10-12 | Corium International | Two-phase, water-absorbent bioadhesive composition |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
US8840918B2 (en) * | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20030175329A1 (en) * | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US20030124174A1 (en) * | 2001-10-25 | 2003-07-03 | Endo Pharmaceuticals, Inc | Method for treating non-neuropathic pain |
CA2729967C (en) * | 2002-12-13 | 2018-01-16 | Schering-Plough Healthcare Products, Inc. | Use of a transdermal or transmucosal ingredient delivery device |
US7888546B2 (en) * | 2003-07-03 | 2011-02-15 | Corium International, Inc. | Wound dressing, ingredient delivery device and IV hold-down, and method relating to same |
KR100552650B1 (ko) * | 2003-11-17 | 2006-02-20 | 아이큐어 주식회사 | 피록시캄 함유 소염진통용 플라스터 |
KR20070007299A (ko) | 2004-01-30 | 2007-01-15 | 코리움 인터네셔널, 인크. | 활성제의 전달을 위한 급속 용해 필름 |
WO2005123046A1 (en) * | 2004-06-15 | 2005-12-29 | Amorepacific Corporation | Novel transdermal preparation and its producing method |
CN103497713B (zh) * | 2004-08-05 | 2018-07-17 | 考里安国际公司 | 粘合剂组合物 |
WO2007016766A1 (en) * | 2005-08-05 | 2007-02-15 | Nuvo Research Inc. | Transdermal drug delivery formulation |
KR101402592B1 (ko) * | 2006-03-06 | 2014-06-17 | 에스케이바이오팜 주식회사 | 피록시캄-무기물 복합체를 포함하는 경피투여 조성물 및이를 이용한 패치시스템 |
KR101304982B1 (ko) * | 2006-05-08 | 2013-09-06 | (주)아모레퍼시픽 | 경피흡수용 조성물 및 이로부터 형성된 고분자 매트릭스함유 경피흡수제제 |
WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
KR100835074B1 (ko) * | 2006-09-27 | 2008-06-03 | 조선대학교산학협력단 | 멜록시캄 경피 흡수제 조성물 및 그의 제조 방법 |
CA2751884C (en) | 2009-01-14 | 2018-09-25 | Corium International, Inc. | Transdermal administration of tamsulosin |
JP6576039B2 (ja) * | 2011-12-21 | 2019-09-18 | スリーエム イノベイティブ プロパティズ カンパニー | オーバーレイライナを有する粘着パッチ組立体、並びにそれを作製するためのシステム及び方法 |
KR101365321B1 (ko) * | 2012-05-22 | 2014-02-20 | 제일약품주식회사 | 매트릭스내 비스테로이드성 소염진통제의 농도구배를 이용하여 경피투과도를 향상시킨 패취제 |
DE102014102400A1 (de) * | 2014-02-25 | 2015-08-27 | Reinhard Caliebe | Topische kosmetische oder pharmazeutische Zusammensetzung |
CA2955241C (en) | 2014-07-18 | 2023-03-28 | Buzzz Pharmaceuticals Limited | Oxymorphone transdermal patch |
KR102590643B1 (ko) * | 2019-01-31 | 2023-10-17 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
KR20210133821A (ko) | 2020-04-29 | 2021-11-08 | 신신제약 주식회사 | 피록시캄을 함유하는 경피 흡수 제제 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS521035A (en) * | 1975-06-19 | 1977-01-06 | Nelson Res & Dev | Vihicle composition containing 11substituted azacycloalkanee22 one |
JPS5815910A (ja) * | 1981-07-07 | 1983-01-29 | メルク・エンド・カムパニ−・インコ−ポレ−テツド | 生物影響剤の皮膚浸透を高めるためのユ−カリプト−ル使用 |
JPS63122631A (ja) * | 1986-10-31 | 1988-05-26 | ファイザー・インコーポレーテッド | 経皮流動増進組成物 |
JPS63160649A (ja) * | 1986-12-24 | 1988-07-04 | ライオン株式会社 | 口腔貼付用基材 |
JPH023613A (ja) * | 1988-02-29 | 1990-01-09 | Pfizer Inc | 経皮吸収増強組成物 |
JPH0278615A (ja) * | 1988-08-02 | 1990-03-19 | Ciba Geigy Ag | 多層性膏薬 |
JPH03251534A (ja) * | 1990-02-27 | 1991-11-11 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
DE3586707T2 (de) * | 1984-10-05 | 1993-02-11 | Hercon Lab | System zur transdermalen applikation eines arzneimittels. |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
US4906475A (en) * | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
-
1993
- 1993-12-31 AU AU57184/94A patent/AU5718494A/en not_active Abandoned
- 1993-12-31 AT AT94903120T patent/ATE202476T1/de active
- 1993-12-31 DE DE69330388T patent/DE69330388T2/de not_active Expired - Lifetime
- 1993-12-31 KR KR1019930032006A patent/KR100212961B1/ko not_active IP Right Cessation
- 1993-12-31 RU RU95113471A patent/RU2110261C1/ru active
- 1993-12-31 BR BR9307754A patent/BR9307754A/pt not_active Application Discontinuation
- 1993-12-31 CA CA002153166A patent/CA2153166A1/en not_active Abandoned
- 1993-12-31 PT PT94903120T patent/PT676962E/pt unknown
- 1993-12-31 EP EP94903120A patent/EP0676962B9/en not_active Expired - Lifetime
- 1993-12-31 ES ES94903120T patent/ES2160623T3/es not_active Expired - Lifetime
- 1993-12-31 WO PCT/KR1993/000127 patent/WO1994015609A1/en active IP Right Grant
- 1993-12-31 JP JP6515882A patent/JP2847578B2/ja not_active Expired - Fee Related
-
1997
- 1997-06-23 AU AU26187/97A patent/AU706123B2/en not_active Ceased
- 1997-10-03 US US08/943,140 patent/US5916587A/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS521035A (en) * | 1975-06-19 | 1977-01-06 | Nelson Res & Dev | Vihicle composition containing 11substituted azacycloalkanee22 one |
JPS5815910A (ja) * | 1981-07-07 | 1983-01-29 | メルク・エンド・カムパニ−・インコ−ポレ−テツド | 生物影響剤の皮膚浸透を高めるためのユ−カリプト−ル使用 |
JPS63122631A (ja) * | 1986-10-31 | 1988-05-26 | ファイザー・インコーポレーテッド | 経皮流動増進組成物 |
JPS63160649A (ja) * | 1986-12-24 | 1988-07-04 | ライオン株式会社 | 口腔貼付用基材 |
JPH023613A (ja) * | 1988-02-29 | 1990-01-09 | Pfizer Inc | 経皮吸収増強組成物 |
JPH0278615A (ja) * | 1988-08-02 | 1990-03-19 | Ciba Geigy Ag | 多層性膏薬 |
JPH03251534A (ja) * | 1990-02-27 | 1991-11-11 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522488A (ja) * | 1998-08-12 | 2002-07-23 | エドコ・トレイディング・アンド・レプレゼンテーション・カンパニー・リミテッド | ニメスリドを含む局所用医薬組成物 |
JP4653308B2 (ja) * | 1998-08-12 | 2011-03-16 | エドコ・パザルラマ・タニティム・ティカレット・リミテッド・シルケティ | ニメスリドを含む局所用医薬組成物 |
JP2005047908A (ja) * | 2003-07-16 | 2005-02-24 | Taisho Pharmaceut Co Ltd | 外用消炎鎮痛剤組成物 |
JP4626202B2 (ja) * | 2003-07-16 | 2011-02-02 | 大正製薬株式会社 | ピロキシカム含有外用消炎鎮痛剤組成物 |
JP2013527197A (ja) * | 2010-05-27 | 2013-06-27 | 株式会社エービーサイズ | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
JP2016033161A (ja) * | 2010-06-17 | 2016-03-10 | 大正製薬株式会社 | 外用組成物 |
JP5758050B2 (ja) * | 2012-06-20 | 2015-08-05 | 久光製薬株式会社 | 貼付剤 |
US9308187B2 (en) | 2012-06-20 | 2016-04-12 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch comprising diclofenac sodium |
WO2014061728A1 (ja) | 2012-10-17 | 2014-04-24 | 味の素株式会社 | 化粧料組成物 |
US10463594B2 (en) | 2012-10-17 | 2019-11-05 | Ajinomoto Co., Inc. | Cosmetic composition |
JP2016515572A (ja) * | 2013-04-04 | 2016-05-30 | ヒュンダイ ファーム カンパニー リミテッド | 皮膚透過が改善された外用剤組成物 |
US10292955B2 (en) | 2013-04-04 | 2019-05-21 | Hyundai Pharm Co., Ltd. | Composition for external use preparation with improved transdermal permeability |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
EP0676962B1 (en) | 2001-06-27 |
EP0676962B9 (en) | 2002-04-03 |
KR100212961B1 (ko) | 1999-08-02 |
AU5718494A (en) | 1994-08-15 |
AU2618797A (en) | 1997-09-04 |
RU2110261C1 (ru) | 1998-05-10 |
ES2160623T3 (es) | 2001-11-16 |
US5916587A (en) | 1999-06-29 |
BR9307754A (pt) | 1995-10-24 |
DE69330388T2 (de) | 2002-01-03 |
WO1994015609A1 (en) | 1994-07-21 |
AU706123B2 (en) | 1999-06-10 |
CA2153166A1 (en) | 1994-07-21 |
PT676962E (pt) | 2001-10-30 |
DE69330388D1 (de) | 2001-08-02 |
JP2847578B2 (ja) | 1999-01-20 |
ATE202476T1 (de) | 2001-07-15 |
EP0676962A1 (en) | 1995-10-18 |
KR940013496A (ko) | 1994-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500365A (ja) | 皮膚浸透力を高めた医薬組成物 | |
US5262165A (en) | Transdermal nitroglycerin patch with penetration enhancers | |
CA2183543C (en) | Sexual steroid-containing transdermal therapeutic systems | |
CA2135925C (en) | Use of glycerin in moderating transdermal drug delivery | |
JP2960832B2 (ja) | エストラジオールの投与システム | |
HU222499B1 (hu) | Ösztradiol-penetrációfokozó szert tartalmazó szabályozott hatóanyag-leadású tapasz és eljárás előállítására | |
PT95245A (pt) | Sistema de matriz solida para a libertacao transdermica de farmacos | |
US5925373A (en) | Transdermal delivery device containing an estrogen | |
WO1982000005A1 (en) | Polymeric diffusion matrix containing a vasodilator | |
CN1400897A (zh) | Lasofoxifene的经皮转运 | |
KR100322988B1 (ko) | 소염진통첩부제조성물및이를함유한소염진통첩부제 | |
EP0486529A1 (en) | Transdermal nitroglycerin patch with penetration enhancers | |
EP2575791B1 (en) | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith | |
JPH0344326A (ja) | 経皮吸収製剤 | |
JP2001002588A (ja) | 経皮エストロゲンアゴニスト・アンタゴニスト療法 | |
JPH0753670B2 (ja) | 経皮・経粘膜製剤 | |
JPH0317018A (ja) | 経皮吸収製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081106 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091106 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091106 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101106 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111106 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131106 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |